The p38 signaling pathway upregulates expression of the Epstein-Barr virus LMP1 oncogene

Journal of Virology

Volumn 84, Issue 6, 2010, Pages 2787-2797

  Johansson, Pegah ^a   Jansson, Ann ^a   Rüetschi, Ulla ^a   Rymo, Lars ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACTIVATING TRANSCRIPTION FACTOR 1; CELL PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ESTROGEN; LATENT MEMBRANE PROTEIN 1; SMALL INTERFERING RNA; SYNAPTOPHYSIN; TRICHOSTATIN A; VIRUS PROTEIN;

APOPTOSIS; ARTICLE; AUTOREGULATION; BINDING SITE; CHROMATIN IMMUNOPRECIPITATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOWN REGULATION; EPSTEIN BARR VIRUS; GENE ACTIVATION; GENE EXPRESSION REGULATION; LYMPHOBLASTOID CELL LINE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION; VIRUS ONCOGENE;

ANIMALS; CELL LINE; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; MAP KINASE SIGNALING SYSTEM; ONCOGENE PROTEINS, VIRAL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROMOTER REGIONS, GENETIC; PROTEINS; RNA, SMALL INTERFERING; RNA, VIRAL; UP-REGULATION; VIRAL MATRIX PROTEINS;

HUMAN HERPESVIRUS 4;

EID: 77649135016     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01052-09     Document Type: Article

References (65)

1. Alessi, D. R., A. Cuenda, P. Cohen, D. T. Dudley, and A. R. Saltiel. 1995. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 270:27489-27494.
2. Bell, A. I., K. Groves, G. L. Kelly, D. Croom-Carter, E. Hui, A. T. Chan, and A. B. Rickinson. 2006. Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays. J. Gen. Virol. 87:2885-2890.
3. Brooks, J. M., S. P. Lee, A. M. Leese, W. A. Thomas, M. Rowe, and A. B. Rickinson. 2009. Cyclical expression of EBV latent membrane protein 1 in EBV-transformed B cells underpins heterogeneity of epitope presentation and CD8+ T cell recognition. J. Immunol. 182:1919-1928.
4. Cahir-McFarland, E., and E. Kieff. 2005. Epstein-Barr Virus latent infection membrane protein 1, p. 553-570. In E. S. Robertson (ed.), Epstein-Barr virus. Caister Academic Press, Norwich, England.
5. Chen, H., J. M. Lee, Y. Zong, M. Borowitz, M. H. Ng, R. F. Ambinder, and S. D. Hayward. 2001. Linkage between STAT regulation and Epstein-Barr virus gene expression in tumors. J. Virol. 75:2929-2937.
6. Chijiwa, T., A. Mishima, M. Hagiwara, M. Sano, K. Hayashi, T. Inoue, K. Naito, T. Toshioka, and H. Hidaka. 1990. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino) ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J. Biol. Chem. 265:5267-5272.
7. Cohen, J. I., F. Wang, J. Mannick, and E. Kieff. 1989. Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc. Natl. Acad. Sci. U. S. A. 86:9558-9562.
8. Craxton, A., G. Shu, J. D. Graves, J. Saklatvala, E. G. Krebs, and E. A. Clark. 1998. p38 MAPK is required for CD40-induced gene expression and proliferation in B lymphocytes. J. Immunol. 161:3225-3236.
9. Cuenda, A., J. Rouse, Y. N. Doza, R. Meier, P. Cohen, T. F. Gallagher, P. R. Young, and J. C. Lee. 1995. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 364:229-233.
10. Cuenda, A., and S. Rousseau. 2007. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim. Biophys. Acta 1773:1358-1375.
11. Dambaugh, T., K. Hennessy, L. Chamnankit, and E. Kieff. 1984. U2 region of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen 2. Proc. Natl. Acad. Sci. U. S. A. 81:7632-7636.
12. Dawson, C. W., G. Tramountanis, A. G. Eliopoulos, and L. S. Young. 2003. Epstein-Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt pathway to promote cell survival and induce actin filament remodeling. J. Biol. Chem. 278:3694-3704.
13. Deak, M., A. D. Clifton, L. M. Lucocq, and D. R. Alessi. 1998. Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB. EMBO J. 17:4426-4441.
14. De Cesare, D., and P. Sassone-Corsi. 2000. Transcriptional regulation by cyclic AMP-responsive factors. Prog. Nucleic Acid Res. Mol. Biol. 64:343-369.
15. Dufva, M., J. Flodin, A. Nerstedt, U. Ruetschi, and L. Rymo. 2002. Epstein-Barr virus nuclear antigen 5 inhibits pre-mRNA cleavage and polyadenylation. Nucleic Acids Res. 30:2131-2143.
16. Eliopoulos, A. G., N. J. Gallagher, S. M. Blake, C. W. Dawson, and L. S. Young. 1999. Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J. Biol. Chem. 274:16085- 16096.
17. Fahraeus, R., L. Palmqvist, A. Nerdstedt, S. Farzad, L. Rymo, and S. Lain. 1994. Response to cAMP levels of the Epstein-Barr virus EBNA2-inducible LMP1 oncogene and EBNA2 inhibition of a PP1-like activity. EMBO J. 13:6041-6051.
18. Floettmann, J. E., K. Ward, A. B. Rickinson, and M. Rowe. 1996. Cytostatic effect of Epstein-Barr virus latent membrane protein-1 analyzed using tetracycline-regulated expression in B cell lines. Virology 223:29-40.
19. Frantz, B., T. Klatt, M. Pang, J. Parsons, A. Rolando, H. Williams, M. J. Tocci, S. J. O'Keefe, and E. A. O'Neill. 1998. The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding. Biochemistry 37:13846-13853.
20. Frevel, M. A., T. Bakheet, A. M. Silva, J. G. Hissong, K. S. Khabar, and B. R. Williams. 2003. p38 mitogen-activated protein kinase-dependent and -independent signaling of mRNA stability of AU-rich element-containing transcripts. Mol. Cell. Biol. 23:425-436.
21. Goormachtigh, G., T. S. Ouk, A. Mougel, D. Tranchand-Bunel, E. Masy, C. Le Clorennec, J. Feuillard, G. W. Bornkamm, C. Auriault, E. Manet, V. Fafeur, E. Adriaenssens, and J. Coll. 2006. Autoactivation of the Epstein-Barr virus oncogenic protein LMP1 during type II latency through opposite roles of the NF-kappaB and JNK signaling pathways. J. Virol. 80:7382-7393.
22. Grasser, F. A., P. Haiss, S. Gottel, and N. Mueller-Lantzsch. 1991. Biochemical characterization of Epstein-Barr virus nuclear antigen 2A. J. Virol. 65:3779-3788.
23. Gregory, C. D., R. J. Murray, C. F. Edwards, and A. B. Rickinson. 1988. Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance. J. Exp. Med. 167:1811-1824.
24. Grossman, S. R., E. Johannsen, X. Tong, R. Yalamanchili, and E. Kieff. 1994. The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the J kappa recombination signal binding protein. Proc. Natl. Acad. Sci. U. S. A. 91:7568-7572.
25. Henkel, T., P. D. Ling, S. D. Hayward, and M. G. Peterson. 1994. Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein J kappa. Science 265:92-95.
26. Herdegen, T., and J. D. Leah. 1998. Inducible and constitutive transcription factors in the mammalian nervous system: control of gene expression by Jun, Fos and Krox, and CREB/ATF proteins. Brain Res. Brain Res. Rev. 28:370-490.
27. Iordanov, M., K. Bender, T. Ade, W. Schmid, C. Sachsenmaier, K. Engel, M. Gaestel, H. J. Rahmsdorf, and P. Herrlich. 1997. CREB is activated by UVC through a p38/HOG-1-dependent protein kinase. EMBO J. 16:1009-1022.
28. Jansson, A., P. Johansson, S. Li, and L. Rymo. 2007. Activity of the LMP1 gene promoter in Epstein-Barr virus-transformed cell lines is modulated by sequence variations in the promoter-proximal CRE site. J. Gen. Virol. 88:1887-1894.
29. Jansson, A., P. Johansson, W. Yang, L. Palmqvist, A. Sjoblom-Hallen, and L. Rymo. 2007. Role of a consensus AP-2 regulatory sequence within the Epstein-Barr virus LMP1 promoter in EBNA2 mediated transactivation. Virus Genes 35:203-214.
30. Johannsen, E., E. Koh, G. Mosialos, X. Tong, E. Kieff, and S. R. Grossman. 1995. Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by J kappa and PU. 1. J. Virol. 69:253-262.
31. Johansson, P., A. Jansson, U. Ruetschi, and L. Rymo. 2009. Nuclear factor-kappaB binds to the Epstein-Barr virus LMP1 promoter and upregulates its expression. J. Virol. 83:1393-1401.
32. Kaiser, C., G. Laux, D. Eick, N. Jochner, G. W. Bornkamm, and B. Kempkes. 1999. The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus nuclear antigen 2. J. Virol. 73:4481-4484.
33. Kaykas, A., and B. Sugden. 2000. The amino-terminus and membrane-spanning domains of LMP-1 inhibit cell proliferation. Oncogene 19:1400-1410.
34. Kempkes, B., M. Pawlita, U. Zimber-Strobl, G. Eissner, G. Laux, and G. W. Bornkamm. 1995. Epstein-Barr virus nuclear antigen 2-estrogen receptor fusion proteins transactivate viral and cellular genes and interact with RBP-J kappa in a conditional fashion. Virology 214:675-679.
35. Kempkes, B., D. Spitkovsky, P. Jansen-Durr, J. W. Ellwart, E. Kremmer, H. J. Delecluse, C. Rottenberger, G. W. Bornkamm, and W. Hammerschmidt. 1995. B-cell proliferation and induction of early G1-regulating proteins by Epstein-Barr virus mutants conditional for EBNA2. EMBO J. 14:88-96.
36. Kieff, E., and A. B. Rickinson. 2001. Epstein-Barr virus and its replication, p. 2511-2574. In D. M. Knipe and P. M. Howley (ed.), Fields virology, 4th ed. Lippincott-Raven Publishers, Philadelphia, PA.
37. Lam, N., M. L. Sandberg, and B. Sugden. 2004. High physiological levels of LMP1 result in phosphorylation of eIF2 alpha in Epstein-Barr virus-infected cells. J. Virol. 78:1657-1664.
38. Laub, O., E. B. Jakobovits, and Y. Aloni. 1980. 5,6-Dichloro-1-beta-ribofuranosylbenzimidazole enhances premature termination of late transcription of simian virus 40 DNA. Proc. Natl. Acad. Sci. U. S. A. 77:3297-3301.
39. Lee, D. Y., and B. Sugden. 2008. The latent membrane protein 1 oncogene modifies B-cell physiology by regulating autophagy. Oncogene 27:2833-2842.
40. Lee, D. Y., and B. Sugden. 2008. The LMP1 oncogene of EBV activates PERK and the unfolded protein response to drive its own synthesis. Blood 111:2280-2289.
41. Ling, P. D., D. R. Rawlins, and S. D. Hayward. 1993. The Epstein-Barr virus immortalizing protein EBNA-2 is targeted to DNA by a cellular enhancer-binding protein. Proc. Natl. Acad. Sci. U. S. A. 90:9237-9241.
42. Lucchesi, W., G. Brady, O. Dittrich-Breiholz, M. Kracht, R. Russ, and P. J. Farrell. 2008. Differential gene regulation by Epstein-Barr virus type 1 and type 2 EBNA2. J. Virol. 82:7456-7466.
43. Mamiya, N., J. R. Goldenring, Y. Tsunoda, I. M. Modlin, K. Yasui, N. Usuda, T. Ishikawa, A. Natsume, and H. Hidaka. 1993. Inhibition of acid secretion in gastric parietal cells by the Ca2+/calmodulin-dependent protein kinase II inhibitor KN-93. Biochem. Biophys. Res. Commun. 195:608-615.
44. Mayr, B., and M. Montminy. 2001. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat. Rev. Mol. Cell Biol. 2:599-609.
45. Narbonnet, S., and B. Mariame. 2006. The Epstein-Barr virus oncoprotein LMP1 inhibits the activity of viral or cellular promoters without inducing cytostasis. Virology 350:381-393.
46. Nelson, J. D., O. Denisenko, and K. Bomsztyk. 2006. Protocol for the fast chromatin immunoprecipitation (ChIP) method. Nat. Protoc. 1:179-185.
47. Ning, S., A. M. Hahn, L. E. Huye, and J. S. Pagano. 2003. Interferon regulatory factor 7 regulates expression of Epstein-Barr virus latent membrane protein 1: a regulatory circuit. J. Virol. 77:9359-9368.
48. Ning, S., L. E. Huye, and J. S. Pagano. 2005. Interferon regulatory factor 5 represses expression of the Epstein-Barr virus oncoprotein LMP1: braking of the IRF7/LMP1 regulatory circuit. J. Virol. 79:11671-11676.
49. Ruegg, U. T., and G. M. Burgess. 1989. Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases. Trends Pharmacol. Sci. 10:218-220.
50. Sample, J., and E. Kieff. 1990. Transcription of the Epstein-Barr virus genome during latency in growth-transformed lymphocytes. J. Virol. 64:1667-1674.
51. Sandberg, M. L., A. Kaykas, and B. Sugden. 2000. Latent membrane protein 1 of Epstein-Barr virus inhibits as well as stimulates gene expression. J. Virol. 74:9755-9761.
52. Sjoblom, A., A. Jansson, W. Yang, S. Lain, T. Nilsson, and L. Rymo. 1995. PU box-binding transcription factors and a POU domain protein cooperate in the Epstein-Barr virus (EBV) nuclear antigen 2-induced transactivation of the EBV latent membrane protein 1 promoter. J. Gen. Virol. 76(Part 11): 2679-2692.
53. Sjoblom, A., W. Yang, L. Palmqvist, A. Jansson, and L. Rymo. 1998. An ATF/CRE element mediates both EBNA2-dependent and EBNA2-independent activation of the Epstein-Barr virus LMP1 gene promoter. J. Virol. 72:1365-1376.
54. Sjoblom-Hallen, A., W. Yang, A. Jansson, and L. Rymo. 1999. Silencing of the Epstein-Barr virus latent membrane protein 1 gene by the Max-Mad1-mSin3A modulator of chromatin structure. J. Virol. 73:2983-2993.
55. Soni, V., E. Cahir-McFarland, and E. Kieff. 2007. LMP1 TRAfficking activates growth and survival pathways. Adv. Exp. Med. Biol. 597:173-187.
56. Tan, Y., J. Rouse, A. Zhang, S. Cariati, P. Cohen, and M. J. Comb. 1996. FGF and stress regulate CREB and ATF-1 via a pathway involving p38 MAP kinase and MAPKAP kinase-2. EMBO J. 15:4629-4642.
57. Tao, Q., L. S. Young, C. B. Woodman, and P. G. Murray. 2006. Epstein-Barr virus (EBV) and its associated human cancers-genetics, epigenetics, pathobiology and novel therapeutics. Front. Biosci. 11:2672-2713.
58. Thorley-Lawson, D. A. 2005. EBV the prototypical human tumor virus-just how bad is it? J. Allergy Clin. Immunol. 116:251-261.
59. Tibbles, L. A., and J. R. Woodgett. 1999. The stress-activated protein kinase pathways. Cell. Mol. Life Sci. 55:1230-1254.
60. Toullec, D., P. Pianetti, H. Coste, P. Bellevergue, T. Grand-Perret, M. Ajakane, V. Baudet, P. Boissin, E. Boursier, F. Loriolle, et al. 1991. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J. Biol. Chem. 266:15771-15781.
61. Waltzer, L., F. Logeat, C. Brou, A. Israel, A. Sergeant, and E. Manet. 1994. The human J kappa recombination signal sequence binding protein (RBP-J kappa) targets the Epstein-Barr virus EBNA2 protein to its DNA responsive elements. EMBO J. 13:5633-5638.
62. Whitmarsh, A. J. 2007. Regulation of gene transcription by mitogen-activated protein kinase signaling pathways. Biochim. Biophys. Acta 1773:1285-1298.
63. Zetterberg, H., and L. Rymo. 2005. EBNA2 transcription regulation in EBV latency, p. 439-462. In E. S. Robertson (ed.), Epstein-Barr virus. Caister Academic Press, Norwich, England.
64. Zetterberg, H., M. Stenglein, A. Jansson, A. Ricksten, and L. Rymo. 1999. Relative levels of EBNA1 gene transcripts from the C/W, F and Q promoters in Epstein-Barr virus-transformed lymphoid cells in latent and lytic stages of infection. J. Gen. Virol. 80(Part 2):457-466.
65. Zimber-Strobl, U., L. J. Strobl, C. Meitinger, R. Hinrichs, T. Sakai, T. Furukawa, T. Honjo, and G. W. Bornkamm. 1994. Epstein-Barr virus nuclear antigen 2 exerts its transactivating function through interaction with recombination signal binding protein RBP-J kappa, the homologue of Drosophila Suppressor of Hairless. EMBO J. 13:4973-4982.